These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

838 related items for PubMed ID: 18627578

  • 1. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH, Chlebicka NL, Low JG, Chong TY, Chan KP, Goh YT.
    Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
    [Abstract] [Full Text] [Related]

  • 2. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
    Solano C, Muñoz I, Gutiérrez A, Farga A, Prósper F, García-Conde J, Navarro D, Gimeno C.
    J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
    [Abstract] [Full Text] [Related]

  • 3. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
    Schulenburg A, Watkins-Riedel T, Greinix HT, Rabitsch W, Loidolt H, Keil F, Mitterbauer M, Kalhs P.
    Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.
    Transpl Infect Dis; 2010 Aug 01; 12(4):322-9. PubMed ID: 20487414
    [Abstract] [Full Text] [Related]

  • 6. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A, Lipton J, Welsh S, Moussa G, Messner H, Mazzulli T.
    Bone Marrow Transplant; 2001 Sep 01; 28(5):485-90. PubMed ID: 11593322
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation.
    Ksouri H, Eljed H, Greco A, Lakhal A, Torjman L, Abdelkefi A, Ben Othmen T, Ladeb S, Slim A, Zouari B, Abdeladhim A, Ben Hassen A.
    Transpl Infect Dis; 2007 Mar 01; 9(1):16-21. PubMed ID: 17313466
    [Abstract] [Full Text] [Related]

  • 9. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
    Piñana JL, Martino R, Barba P, Margall N, Roig MC, Valcárcel D, Sierra J, Rabella N.
    Bone Marrow Transplant; 2010 Mar 01; 45(3):534-42. PubMed ID: 19668235
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
    Hazar V, Ugur A, Colak D, Saba R, Tezcan G, Kupesiz A, Karadogan I, Gultekin M, Yesilipek A, Undar L.
    Jpn J Infect Dis; 2006 Aug 01; 59(4):216-21. PubMed ID: 16936338
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F, Tscheliessnigg KH, Halwachs G, Auer T, Wasler A, Petutschnigg B, Müller H, Freigassner M, Allmayr T, Hipmair G.
    Wien Klin Wochenschr; 1995 Aug 01; 107(23):718-22. PubMed ID: 8560893
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
    Alberú J, Morales-Buenrostro LE, Correa-Rotter R, Muñoz-Trejo T, Zúñiga-Varga J, Cuéllar-González JV, Mayorga-Madrigal H, Vanegas-Carrero R, Aranda F, Rodríguez-Romo R, Herrera-Garcia C, González-Michaca L, Sierra-Madero JG.
    Rev Invest Clin; 2008 Aug 01; 60(5):365-74. PubMed ID: 19227433
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
    Lo CY, Ho KN, Yuen KY, Lui SL, Li FK, Chan TM, Lo WK, Cheng IK.
    Clin Transplant; 1997 Aug 01; 11(4):286-93. PubMed ID: 9267717
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.